Molecular Transducers of Physical Activity Consortium

Completed · Not applicable

Conditions studied: Physical Activity

In brief

The goal of the Molecular Transducers of Physical Activity Consortium (MoTrPAC) is to assess molecular changes that occur in response to physical activity (PA). To achieve this aim, a mechanistic randomized controlled trial (RCT) is conducted, in which adult study participants are randomized to endurance exercise (EE) training, resistance exercise (RE) training, or no exercise Control for a period of approximately 12 weeks. The overarching hypothesis is that there are discoverable molecular transducers that communicate and coordinate the effects of exercise on cells, tissues, and organs, which may initiate processes ultimately leading to the health benefits of exercise. Because this is a mechanistic trial, the main goal is not a single health-related outcome. Rather, the goal is to generate a resource leading to the generation of a map of the molecular responses to exercise that will be used by the Consortium and by the scientific community at large to generate hypotheses for future investigations of the health benefits of PA.

Key facts

Study ID

NCT03960827

Run by

Wake Forest University Health Sciences

People needed

1836

Starts

2019-08-28

Expected to finish

2025-05-31

Last updated by the study team

2026-07-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may not qualify if…

• ADULT PARTICIPANT EXCLUSION CRITERIA Exclusion criteria are confirmed by self-report (i.e., medical and medication histories reviewed by a clinician), screening tests performed by the MoTrPAC study team at each clinical site, and/or clinician judgement as specified for each criterion.
• Diabetes (self-report and screening tests)
• Treatment with any hypoglycemic agents (self-report) or A1c >6.4% (screening test; may reassess once if 6.5-6.7%)
• Fasting glucose >125 mg/dL (screening test; may reassess once)
• Use of hypoglycemic drugs for non-diabetic reasons (self-report)
• Abnormal bleeding or coagulopathy (self-report)
• History of a bleeding disorder or clotting abnormality
• Thyroid disease (screening test)
• Thyroid Stimulating Hormone (TSH) value >5.9 IU/mL
• Individuals with hypothyroidism may be referred to their primary care provider (PCP) for evaluation and retested; any medication change must be stable for ≥3 months prior to retesting
• Individuals with hyperthyroidism are excluded, including those with normal TSH on pharmacologic treatment
• Pulmonary (self-report)
• Clinical diagnosis of Chronic Obstructive Pulmonary Disease (COPD)
• Metabolic bone disease (self-report)
• History of non-traumatic fracture from a standing height or less
• Current pharmacologic treatment for low bone mass or osteoporosis, other than calcium, vitamin D, or estrogen
• Estrogens, progestins (self-report)
• Supplemental, replacement or therapeutic use of estrogens or progestins within the last 6 months, other than birth control or to control menopausal symptoms
• Pregnancy (screening test) and pregnancy-related conditions (self-report)
• Pregnant - pregnancy test performed on day of DXA scan in women of child-bearing potential
• Post-partum during the last 12 months
• Lactating during the last 12 months
• Planning to become pregnant during the participation period
• Elevated blood pressure readings (screening test)
• Resting Systolic Blood Pressure (SBP) ≥150 mmHg or Resting Diastolic Blood Pressure (DBP) ≥95 mmHg

Where it is running

• University of Alabama at Birmingham — Birmingham, Alabama, United States
• Cedars-Sinai Medical Center — Los Angeles, California, United States
• University of Colorado Denver — Denver, Colorado, United States
• Florida Hospital / Advent Health — Orlando, Florida, United States
• Ball State University — Muncie, Indiana, United States
• Pennington Biomedical Research Center — Baton Rouge, Louisiana, United States
• Duke University Medical Center — Durham, North Carolina, United States
• East Carolina University — Greenville, North Carolina, United States
• University of Pittsburgh — Pittsburgh, Pennsylvania, United States
• University of Texas Medical Branch - Galveston — Galveston, Texas, United States
• University of Texas Health Science Center, San Antonio — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.